A Message from Our CEO
Thank you for your interest in IQuity. We recognize patients are looking for answers. We also know that diagnosing and treating patients with autoimmune disease can be challenging. As we developed our research program, we have established a firm commitment to translating bench innovations into clinical practice.
IQuity was founded by scientists leveraging technology developed at Vanderbilt University Medical Center over the past 10 years. With funding from the National Institutes of Health and private investment, we are committed to bringing this new technology to communities that are desperately seeking advancements in diagnosis and treatment.
Our commitment is to transparency. IQuity’s science, processes and analytic capabilities are an open book. Through our website, scientific poster presentations and published papers, we are eager to share with you what we do, how we do it and ways we believe we can be of value to the healthcare community.
— Chase Spurlock, Ph.D., CEO of IQuity
When we were launching IQuity, I made an intentional effort to talk with people who had been diagnosed with an autoimmune disease. I wanted to know what I couldn’t find out in the lab – like how it feels to learn you have a life-altering, incurable disease. After all, how you feel about something determines what you do about it. IQuity makes it possible to know quite quickly, and with a high degree of confidence, whether that tingling in your leg is simply because you sat with your legs crossed too long or is an early symptom of multiple sclerosis (MS).